Fotona D.O.O. appears in FDA device records as the applicant behind a series of 510(k) submissions for the Dynamis Pro Family, a laser surgical instrument line for general and plastic surgery and dermatology. The supplied collection, retrieved as of November 20, 2026, links one record to this applicant: K252723, a Traditional 510(k) with a Substantially Equivalent decision dated September 19, 2026. The record sits under product code GEX and advisory committee General, Plastic Surgery. Earlier filings in the numbered sources show the same trade name and regulation number recurring across more than a decade of submissions. [1][2][4]
The 2026 clearance and its stated scope
K252723 covers the Dynamis Pro Family under regulation number 21 CFR 878.4810, Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology, Class II, product code GEX. The submission was received August 28, 2025, and decided September 19, 2026, with decision code SESE and the description Substantially Equivalent. The record lists a Summary rather than a statement, a Traditional clearance type, no third-party review, and the review advisory committee as General, Plastic Surgery. [1][2]
The decision letter is addressed to Tina Bartolic, Quality Assurance and Regulatory Affairs Specialist, at Stegne 7, Ljubljana, Slovenia, and identifies the applicant as Fotona d.o.o. The letter restates the trade name, regulation, class and product code, and notes the submission was dated September 14. The correspondence address in a filing is not evidence of a corporate headquarters. [2]
Device configuration and indications in the filing
The Dynamis Pro Family is described as operating in single-wavelength configurations, Nd:YAG or Er:YAG, and dual-wavelength configurations combining both. Integrated technology allows control of laser energy and pulse duration, and the user activates emission with a footswitch. The 2026 filing describes the device configuration as a system console and handpiece. [8][2]
The 2026 submission states an Er:YAG indication for improving the appearance of scalp hair in adults with Fitzpatrick skin type I to IV seeking treatment for hair loss, and describes soft tissue resurfacing. It characterizes the change relative to a predicate as a different clinical outcome with the same mechanism of action and handpiece as the reference device. [2]
Earlier submissions under the same trade name
K143723, dated January 7, 2015 and cleared April 9, 2015, named the Fotona Dynamis Pro Family under the same regulation and class, with product codes GEX and ONG. The applicant contact then was Stojan Trošt, Quality Assurance & Regulatory Affairs Manager. [8]
K182088, dated July 27, 2018 and received August 2, 2018, repeated the Dynamis Pro Family trade name, regulation, class and product code GEX, addressed to Marko Berdajs. That submission stated the device had the same design and functional features as its predicate and asserted substantial equivalence to the Fotona Dynamis Pro Family cleared under K143723. K213267, dated and received July 27, 2022 and decided September 8, 2022, again covered the Dynamis Pro Family under the same regulation, class and product code, and concluded substantial equivalence to its predicate devices. [4][5]
Published product material and record limits
Fotona's own Dynamis Pro brochure describes multi-application laser systems and lists key benefits including tissue-selective treatments, parameter selection, treatment modes, accessories, minimally invasive treatments with short downtime, and patient comfort. A Fotona product page for the SP Dynamis Pro states that the device uses two complementary laser wavelengths and supports applications in aesthetics, surgery and gynecology. These are the publisher's characterizations, not independently verified findings. [6][7]
The supplied collection links one 510(k) record to this applicant, and the sample of linked records contains that same single entry with a Substantially Equivalent decision. These counts describe the retrieved filings as of the snapshot date; they are not measures of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1]

